British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019)

Holland J Young ML Lee O , et al. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 2003; 79: 249–250.

Wang FJ Zhang D Liu ZH , et al. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin Med J 2016; 129: 1161–1165.

Guerrero-Lozano I Aznar-Marin P Garcia-Agudo L , et al. Vulvovaginal candidosis by non-albicans Candida species. Mycoses 2012; 55(4): 205.

Bulik CC Sobel JD Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction – impact of two decades. Mycoses 2011; 54: 34–38.

Marchaim D Lemanek L Bheemreddy S , et al. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012; 120: 1407–1414.

Gross NT Arias ML Moraga M , et al. Species distribution and susceptibility to azoles of vaginal yeasts isolated prostitutes. Infect Dis Obstet Gynecol 2007; 2007: 82412.

Araj GF Asmar RG Avedissian AZ. Candida profiles and antifungal resistance evolution over a decade in Lebanon. J Infect Dev Ctries 2015; 9: 997–1003.

Hetticarachchi N Ashbee HR Wilson JD. Prevalence and management of non-albicans vaginal candidiasis. Sex Transm Infect 2010; 86: 99–100.

Dennerstein GJ Ellis DH Reed CS , et al. Pathogenicity of non-albicans yeasts in the vagina. J Low Genit Tract Dis 2011; 15: 33–36.

Zeng J Zong LL Mao T , et al. Distribution of Candida albicans genotype and Candida species is associated with the severity of vulvovaginal candidiasis. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 1649–1653.

Hurley R De Louvois J. Candida vaginitis. Postgrad Med J 1979; 55: 645–647.

Denning DW Kneale M Sobel JD , et al. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis 2018; 18: e339–e347.

Hurley R. Recurrent Candida infection. Clin Obstet Gynaecol 1981; 8: 209–214.

Foxman B Muraglia R Dietz JP , et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 2013; 17: 340–345.

Fidel PL Jr Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 9: 335–348.

El-Din SS Reynolds MT Ashbee HR , et al. An investigation into the pathogenesis of vulvo-vaginal candidosis. Sex Transm Infect 2001; 77: 179–183.

Patel D Gillespie B Sobel J , et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol 2004; 190: 644–653.

van de Wijgert JH Verwijs MC Turner AN , et al. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 2013; 27: 2141–2153.

Donders GG Mertens I Bellen G , et al. Self-elimination of risk factors for recurrent vaginal candidosis. Mycoses 2011; 54: 39–45.

Fischer G Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis 2011; 15: 263–267.

Pirotta MV Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 2006; 44: 3213–3217.

Oliveira CS Gandra R Loth EA , et al. Clinical, epidemiological and laboratory findings among women with recurrent vulvovaginal candidiasis (RVVC) in an university hospital, Brazil. Mycoses 2015; 58: 68(P038).

Yano J Kolls JK Happel KI , et al. The acute neutrophil response mediated by S100 alarmins during vaginal Candida infections is independent of the Th17-pathway. PLoS One 2012; 7: e46311.

Odds FC Webster CE Mayuranathan P , et al. Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. J Med Vet Mycol 1988; 26: 277–283.

Fidel PL Barousse M Espinosa T , et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004; 72: 2939–2946.

Moraes PS. Recurrent vaginal candidiasis and allergic rhinitis: a common association. Ann Allergy Asthma Immunol 1998; 81: 165–169.

Ehrstrom S Kornfeld D Rylander E. Perceived stress in women with recurrent vulvovaginal candidiasis. J Psychosom Obstet Gynaecol 2007; 28: 169–176.

Akimoto-Gunther L Bonfim-Mendonça PdS Takahachi G , et al. Highlights regarding host predisposing factors to recurrent vulvovaginal candidiasis: chronic stress and reduced antioxidant capacity. PLoS One 2016; 11: e0158870.

Spacek J Jilek P Buchta V , et al. The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls. Mycoses 2005; 48: 391–395.

Naderi N Etaati Z Rezvani Joibari M , et al. Immune deviation in recurrent vulvovaginal candidiasis: correlation with iron deficiency anemia. Iran J Immunol 2013; 10: 118–126.

Bohler K Meisinger V Klade H , et al. Zinc levels of serum and cervicovaginal secretion in recurrent vulvovaginal candidiasis. Genitourin Med 1994; 70: 308–310.

Henić E Thiel S Mårdh PA. Mannan-binding lectin in women with a history of recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 2010; 148: 163–165.

Donders GG Babula O Bellen G , et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115: 1225–1231.

Nedovic B Posteraro B Leoncini E , et al. Mannose-binding lectin codon 54 gene polymorphism and vulvovaginal candidiasis: a systematic review and meta-analysis. Biomed Res Int 2014; 2014: 738298–738299.

Apalata T Longo-Mbenza B Sturm A , et al. Factors associated with symptomatic vulvovaginal candidiasis: a study among women attending a primary healthcare clinic in Kwazulu-Natal, South Africa. Ann Med Health Sci Res 2014; 4: 410–416.

Narayankhedkar A Hodiwala A Mane A. Clinicoetiological characterization of infectious vaginitis amongst women of reproductive age group from Navi Mumbai, India. J Sex Transm Dis 2015; 2015: 817092.

Beikert FC Le MT Koeninger A , et al. Recurrent vulvovaginal candidosis: focus on the vulva. Mycoses 2011; 54: e807–e810.

Zhu YX Li T Fan SR , et al. Health-related quality of life as measured with the short-form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. Health Qual Life Outcomes 2016; 14: 65.

Hong E Dixit S Fidel PL , et al. Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition. J Low Genit Tract Dis 2014; 18: 31–38.

Spacek J Buchta V Jílek P , et al. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 2007; 131: 198–202.

Schaaf VM Perez-Stable EJ Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med 1990; 150: 1929–1933.

Geiger AM Foxman B Sobel JD. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no Candida. Genitourin Med 1995; 71: 304–307.

Lanternier F Cypowyj S Picard C , et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr 2013; 25: 736–747.

Ferris DG Dekle C Litaker MS. Women’s use of over-the-counter antifungal medications for gynaecologic symptoms. J Fam Pract 1996; 42: 595–600.

Lev-Sagie A Witkin SS. Recent advances in understanding provoked vestibulodynia. F1000Res 2016; 5: 2581.

Harlow BL, Caron RE Parker SE , et al. Recurrent yeast infections and vulvodynia: can we believe associations based on self-reported data? J Womens Health 2017; 26: 1069–1076.

Mason MJ Winter AJ. How to diagnose and treat aerobic and desquamative inflammatory vaginitis. Sex Transm Infect 2017; 93: 8–10.

Cibley LJ Cibley LJ. Cytolytic vaginosis. Am J Obstet Gynecol 1991; 165: 1245–1249.

Xu H Zhang X Yao W , et al. Characterization of the vaginal microbiome during cytolytic vaginosis using high-throughput sequencing. J Clin Lab Anal 2018; 10: e22653.

Lindner JG Plantema FH Hoogkamp K. Quantitative studies of the vaginal flora of healthy women and of obstetric and gynaecological patients. J Med Microbiol 1978; 11: 233–224.

Odds FC. Candida and candidosis; a review and bibliography. 2nd ed. London: Bailliere Tindall, 1988.

Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. Ann Emerg Med 1995; 25: 587–591.

Bergman JJ Berg AO Schneeweiss R , et al. Clinical comparison of microscopic and culture techniques in the diagnosis of Candida vaginitis. J Fam Pract 1984; 18: 549–552.

Eckert LO Hawes SE Stevens CE , et al. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998; 92: 757–765.

Sonnex C Lefort W. Microscopic features of vaginal candidiasis and their relation to symptomatology. Sex Transm Infect 1999; 75: 417–419.

Zdolsek B Hellberg D Froman G , et al. Culture and wet smear microscopy in the diagnosis of low-symptomatic vulvovaginal candidosis. Eur J Obstet Gynecol Reprod Biol 1995; 58: 47–51.

Liu XP Fan SR. Methylrosaniline chloride stained vaginal smears for the diagnosis of vulvovaginal candidiasis. Int J Gynaecol Obstet 2007; 99: 83–86.

Hopwood V Crowley T Horrocks CT , et al. Vaginal candidosis: relation between yeast counts and symptoms and clinical signs in non-pregnant women. Genitourin Med 1988; 64: 331–334.

Odds FC Webster CE Riley VC , et al. Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes. Eur J Obstet Gynecol Reprod Biol 1987; 25: 53–66.

Priestley CJ Jones BM Dhar J , et al. What is normal vaginal flora? Genitourin Med 1997; 73: 23–28.

Singh RH Erbelding EJ Zenilman JM , et al. The role of the speculum and bimanual examinations when evaluating attendees at a sexually transmitted diseases clinic. Sex Transm Infect 2007; 83: 206–201.

Barnes P Vieira R Chauhan M. Self-taken vaginal swabs versus clinician-taken for detection of candida and bacterial vaginosis: a case-control study in primary care. Br J Gen Pract 2017; 67: e824–e829.

Royal College of General Practitioners (RCGP)/British Association for Sexual Health and HIV (BASHH). Sexually transmitted infections in primary care, https://www.bashhguidelines.org/media/1089/sexually-transmitted-infections-in-primary-care-2013.pdf (2013, accessed 29 January 2019).

Standards Unit, Microbiology Services, Public Health England. UK Standards for Microbiology Investigations: Investigations of Genital Tract and Associated Specimens. B28i4.6, https://www.gov.uk/government/publications/smi-b-28-investigation-of-genital-tract-and-associated-specimens (2017, accessed 27 March 2019).

Engberts MK Boon ME van Haaften M , et al. Symptomatic candidiasis: using self sampled vaginal smears to establish the presence of Candida, lactobacilli, and Gardnerella vaginalis. Diagn Cytopathol 2007; 35: 635–639.

Vergers-Spooren HC van der Meijden WI Luijendijk A , et al. Self-sampling in the diagnosis of recurrent vulvovaginal candidosis. J Low Genit Tract Dis 2013; 17: 187–192.

Danby CS Boikov D Rautemaa-Richardson R , et al. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother 2012; 56: 1403–1406.

Spitzer M Wiederhold NP. Reduced antifungal susceptibility of vulvovaginal Candida species at normal vaginal pH levels: clinical implications. J Low Genit Tract Dis 2018; 22: 152–158.

Cartwright CP Lembke BD Ramachandran K , et al. Comparison of nucleic acid amplification assays with BD affirm VPIII for diagnosis of vaginitis in symptomatic women. J Clin Microbiol 2013; 51: 3694–3699.

Chatwani AJ Mehta R Hassan S , et al. Rapid testing for vaginal yeast detection: a prospective study. Am J Obstet Gynecol 2007; 196: 309.

Dan M Leshem Y Yeshaya A , et al. Performance of a rapid yeast test in detecting Candida spp. in the vagina. Diagn Microbiol Infect Dis 2010; 67: 52–55.

Elegbe IA Elegbe I. Quantitative relationships of Candida albicans infections and dressing patterns in Nigerian women. Am J Public Health 1983; 73: 450–452.

Ekpenyong CE Inyang-Etoh EC Ettebong EO , et al. Recurrent vulvovaginal candidosis among young women in south eastern Nigeria: the role of lifestyle and health-care practices. Int J STD AIDS 2012; 23: 704–709.

Pontes AC Amaral RL Giraldo PC , et al. A systematic review of the effect of daily panty liner use on the vulvovaginal environment. Int J Gynaecol Obstet 2014; 127: 1–5.

Giraldo PC Amaral RL Juliato C , et al. The effect of “breathable” panty liners on the female lower genital tract. Int J Gynaecol Obstet 2011; 115: 61–64.

Janković S Bojović D Vukadinović D , et al. Risk factors for recurrent vulvovaginal candidiasis. Vojnosanit Pregl 2010; 67: 819–824.

Shaaban OM Abbas AM Moharram AM , et al. Does vaginal douching affect the type of candidal vulvovaginal infection? Med Mycol 2015; 53: 817–827.

Heng LS Yatsuya H Morita S , et al. Vaginal douching in Cambodian women: its prevalence and association with vaginal candidiasis. J Epidemiol 2010; 20: 70–76.

Edwards L Lynch P. Genital dermatology atlas. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2004.

Watson C Fairley C Garland S , et al. The effect of sexual intercourse on vaginal colonisation with candida. Sex Transm Infect 2015; 91: A119–A120 (P06.14).

Eisen DP Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003; 37: 1496–1505.

Watson MC Grimshaw JM Bond CM , et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG 2002; 109: 85–95.

Nurbhai M Grimshaw J Watson M , et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2007; 4: CD002845.

Lopez M Ester J. Candidiasis (vulvovaginal). BMJ Clin Evid 2015; 2015: 0815.

Pitsouni E Iavazzo C Falagas ME. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2008; 198: 153–160.

Sekhavat L Tabatabaii A Tezerjani FZ. Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis. J Infect Public Health 2011; 4: 195–199.

Mølgaard-Nielsen D Svanström H Melbye M , et al. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016; 315: 58–67.

Daniel S Rotem R Koren G , et al. Vaginal antimycotics and the risk for spontaneous abortions. Am J Obstet Gynecol 2018; 218: 601.e1–601.e7.

Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, http://www.cdc.gov/std/tg2015/default.htm (2015, accessed 4 February 2019).

Sobel JD Kapernick PS Zervos M , et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185: 363–369.

Sobel JD Brooker D Stein GE , et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995; 72: 1263–1268.

Fan S Liu X Liang Y. Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. Gynecol Obstet Invest 2015; 80: 113–118.

Zhou X Li T Fan S , et al. The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. Mycoses 2016; 59: 419–428.

Sobel JD Faro S Force RW , et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203–211.

Rosa MI Silva BR Pires PS , et al. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013; 167: 132–136.

Neves NA Carvalho LP Lopes AC , et al. Successful treatment of refractory recurrent vaginal candidiasis with cetirizine plus fluconazole. J Low Genit Tract Dis 2005; 9: 167–170.

Perlin DS Shor E Zhao Y. Update on antifungal drug resistance. Curr Clin Microbiol Rep 2015; 2: 84–95.

European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-marketing-authorisations-oral-ketoconazole (2013, accessed 4 February 2019).

Donders G Bellen G Byttebier G , et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008; 199: 613.

Nguyen Y Lee A Fischer G. Management of chronic vulvovaginal candidiasis: a long term retrospective study. Australas J Dermatol 2017; 58: e188–e192.

Sobel J Chaim W Nagappan V , et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003; 189: 1297–1300.

Singh S Sobel J Bhargava P , et al. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002; 35: 1066–1070.

Dressen G Kusche W Neumeister C , et al. Diagnosis of vulvovaginal candidiasis and effectiveness of combined topical treatment with nystatin: results of a non-interventional study in 973 patients. Open Womens Health J 2012; 6: 19–23.

Khameneie KM Arianpour N Roozegar R , et al. Fluconazole and boric acid for treatment of vaginal candidiasis – new words about old issue. East Afr Med J 2013; 90: 117–123.

Iavazzo C Gkegkes ID Zarkada IM , et al. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health 2011; 20: 1245–1255.

Guaschino S De Seta F Sartore A , et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2001; 184: 598–602.

Acs N Bunhidy F Puh E , et al. Teratogenic effects of vaginal boric acid treatment during pregnancy. Int J Gynaecol Obstet 2006; 93: 55–56.

Phillips A. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005; 192: 2009–2012.

White DJ Habib AR Vanthuyne A , et al. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Infect 2001; 77: 212–213.

Fan S Liu X Wu C , et al. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia 2015; 179: 95–101.

Young GL Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001; 4: CD000225.

Bauters T Dhont M Temmerman M , et al. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569–574.

Kent Pharmaceuticals Ltd. Fluconazole 150 mg capsules: summary of product characteristics, https://www.medicines.org.uk/emc/product/3246/smpc (2019, accessed 31 July 2019).

Alsaad AM Kaplan YC Koren G. Exposure to fluconazole and risk of congenital malformations in the offspring: a systematic review and meta-analysis. Reprod Toxicol 2015; 52: 78–82.

Howley MM Carter TC Browne ML , et al. Fluconazole use and birth defects in the National Birth Defects Prevention Study. Am J Obstet Gynecol 2016; 214: 657.

Mogensen DM Pihl MB Skakkebæk NE , et al. Prenatal exposure to antifungal medication may change anogenital distance in male offspring: a preliminary study. Environ Health 2017; 16: 68.

National Poisons Information Service, www.toxbase.org (accessed 11 April 2019).

Cotch MF Hillier SL Gibbs RS , et al. Epidemiology and outcomes associated with moderate to heavy Candida colonisation during pregnancy. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1998; 178: 374–380.

Farr A Kiss H Holzer I , et al. Effect of asymptomatic vaginal colonisation with Candida albicans on pregnancy outcome. Acta Obstet Gynecol Scand 2015; 94: 989–996.

Bánhidy F Dudás I , and Czeize AE , Preconceptional screening of sexually transmitted infections/diseases. Cent Eur J Med 2010; 6: 49–57.

Roberts CL Algert CS Rickard KL , et al. Treatment of vaginal candidiasis for the prevention of preterm birth: a systematic review and meta-analysis. Syst Rev 2015; 4: 31.

Tellapragada C Eshwara VK Bhat P , et al. Screening of vulvovaginal infections during pregnancy in resource constrained settings: implications on preterm delivery. J Infect Public Health 2017; 10: 431–437.

Lewis H Pruski P Kindinger L , et al. Relationship between yeast, vaginal microbiota composition and pregnancy outcomes. Reprod Sci 2017; 24: 1A–51A.

Holzer I Farr A Kiss H , et al. The colonisation with Candida species is more harmful in the second trimester of pregnancy. Arch Gynecol Obstet 2017; 295: 891–895.

White DJ Vanthuyne A Wood PM , et al. Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study. Sex Transm Infect 2004; 80: 219–222.

Xie HY Feng D Wei DM , et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev 2017; 11: CD010496.

Kalliomaki M Salminen S Arvilommi H , et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–1079.

Hammer KA Carson CF Riley TV. In-vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree oil products, against Candida spp. J Antimicrob Chemother 1998; 42: 591–595.

D’Antuono A Baldi E Bellavista S , et al. Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness. Mycoses 2012; 55: e85–e89.

Abdelmonem AM Rasheed SM Mohamed AS. Bee-honey and yogurt: a novel mixture for treating patients with vulvovaginal candidiasis during pregnancy. Arch Gynecol Obstet 2012; 286: 109–114.

Darvishi M Jahdi F Hamzegardeshi Z , et al. The comparison of vaginal cream of mixing yogurt, honey and clotrimazole on symptoms of vaginal candidiasis. Glob J Health Sci 2015; 7: 108–116.

Mardh PA Rodrigues AG Genc M , et al. Facts and myths on recurrent vulvovaginal candidosis – a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002; 3: 522–539.

Watson CJ Grando D Fairley CK , et al. The effects of oral garlic on vaginal candida colony counts: a randomised placebo controlled double-blind trial. BJOG 2014; 121: 498–506.

Bohannon NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care 1998; 21: 451–456.

Goswami D Goswami R Banerjee U , et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect 2006; 52: 111–117.

Akimoto-Gunther L Bonfim-Mendonca PS Godoy JSR , et al. Hyperglycemia and increased risk of vulvovaginal candidiasis (VVC). Mycoses 2015; 58: 168 (P316).

Ray D Goswami R Banerjee U , et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30(2): 312–317.

Duerr A Heilig CM Meikle SF , et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: risk factors and severity. Obstet Gynecol 2003; 101(3): 548–556.

Apalata T Carr WH Sturm WA , et al. Determinants of symptomatic vulvovaginal candidiasis among human immunodeficiency virus type 1 infected women in rural KwaZulu-Natal, South Africa. Infect Dis Obstet Gynecol 2014; 387070.

Sobel J. Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. Int J STD AIDS 2002; 13: 358–362.

Baka S Tsouma I Logothetis E , et al. Pathogens implicated in cases of vulvovaginitis in prepubertal and pubertal girls. Clin Microbiol Infect 2012; 18: 233–234 (P1009).

Spinillo A Pizzoli G Colonna L , et al. Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol 1993; 81: 721–727.

Donders G Bellen G Janssens D , et al. Influence of contraceptive choice on vaginal bacterial and fungal microflora. Eur J Clin Microbiol Infect Dis 2017; 36: 43–48.

Camacho DP Consolaro ME Patussi EV , et al. Vaginal yeast adherence to the combined contraceptive vaginal ring (CCVR). Contraception 2007; 76: 439–443.

Veres S Miller L Burington B. A comparison between the vaginal ring and oral contraceptive. Obstet Gynecol 2004; 104: 555–563.

Wang LY OuYang L Tong F , et al. The effect of contraceptive methods on reproductive tract infections risk: a cross-sectional study having a sample of 52,481 women. Arch Gynecol Obstet 2016; 294: 1249–1256.

Guzel AB Ilkit M Akar T , et al. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species. Med Mycol 2011; 49: 16–25.

Auler ME Morreira D Rodrigues FF , et al. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Med Mycol 2010; 48: 211–216.

Chassot F Negri M Svidzinski A , et al. Can intrauterine contraceptive devices be a Candida albicans reservoir. Contraception 2008; 77: 359.

Güdücü N Gönenç G Işçi H , et al. Clinical importance of detection of bacterial vaginosis, Trichomonas vaginalis, Candida albicans and actinomyces in Papanicolaou smears. Clin Exp Obstet Gynecol 2012; 39: 333–336.

Behboudi-Gandevani S Imani S Moghaddam-Banaem L , et al. Can intrauterine contraceptive devices lead to vulvovaginal candidiasis (VVC) and anemia in Iranian new users? Sex Reprod Healthc 2015; 6: 40–43.

Donders G Bellen G Ruban K , et al. Short- and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena) on vaginal microbiota and Candida. J Med Microbiol 2018; 67: 308–313.

Cakiroglu Y Caliskan S Doger E , et al. Does removal of CU-IUD in patients with biofilm forming candida really maintain regression of clinical symptoms? J Obstet Gynaecol 2015; 35: 600–603.

Bisschop MP Merkus JM Scheygrond H , et al. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. Br J Obstet Gynaecol 1986; 93: 79–81.

Fong IW. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 1992; 68: 174–176.

Lisboa C Costa AR Ricardo E , et al. Genital candidosis in heterosexual couples. J Eur Acad Dermatol Venereol 2011; 25: 145–151.

Spence D. Candidiasis (vulvovaginal). BMJ Clin Evid 2010; 5: 2010.